Literature DB >> 1587065

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.

A Munafo1, Y Christen, J Nussberger, L Y Shum, R M Borland, R J Lee, B Waeber, J Biollaz, H R Brunner.   

Abstract

The aim of this study was to investigate the relationships between plasma concentrations of losartan, an orally active angiotensin II inhibitor, its active metabolite EXP3174, and angiotensin II blockade. Six healthy subjects received single oral doses of 40, 80, or 120 mg losartan and placebo at 1-week intervals in a crossover study. Angiotensin II blockade was assessed by the blood pressure response to exogenous angiotensin II before and after losartan administration. EXP3174 reached higher plasma concentrations and was eliminated more slowly than its parent compound; its levels paralleled the profile of angiotensin II blockade closer than losartan. Inhibition of the pressure response was dose dependent. The Hill-shaped relationship between response and EXP3174 concentration (or time-integrated variables) approached a plateau with 80 mg. The dose-dependent increase in plasma renin and angiotensin II exhibited a considerable individual scatter. We conclude that losartan produces a dose-dependent, effective angiotensin II blockade that is largely determined by the active metabolite EXP3174.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1587065     DOI: 10.1038/clpt.1992.56

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

1.  Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Authors:  Chantal Csajka; Thierry Buclin; Karin Fattinger; Hans R Brunner; Jérôme Biollaz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.

Authors:  J Scholze; M Stapff
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 4.  A risk-benefit assessment of losartan potassium in the treatment of hypertension.

Authors:  L M Burrell
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

Review 5.  Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Authors:  C Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 6.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

7.  An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.

Authors:  R L Byyny; D D Merrill; T E Bradstreet; C S Sweet
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

8.  Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system.

Authors:  C Buchwalder-Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

9.  Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.

Authors:  Kazuishi Sekino; Takahiro Kubota; Yuko Okada; Yasuhiko Yamada; Koujirou Yamamoto; Ryuya Horiuchi; Kenjirou Kimura; Tatsuji Iga
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

10.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.